MARCH 30 2021
Glytec announced today that it introduced the latest version of its eGlycemic Management System (eGMS) for managing insulin.
Waltham, Mass.-based Glytec’s eGMS is centered around the FDA-cleared Glucommander algorithm, which leverages real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs, leading to a personalized treatment regime that can reduce hypoglycemia, hyperglycemia, lengths of stay, readmissions and cost of care, according to a news release.
Enhancements to the latest version of the eGMS software platform include ways to reduce workflow friction for clinicians and further improve patient safety, Glytec said.
Order set initiation allows for the Glucommander to automatically receive initial parameters as ordered by the provider, while medication dose confirmation sees data sent to the EMR flowsheet and displayed in the medication administration record so a nurse can view and chart the administration of the dose before sending information back to the Glucommander to confirm the actual dose that was given.
Additionally, the new enhancements allow for Glucommander SubQ, which leverages the laboratory interfaces to recover overnight blood glucose (BG) values that were not entered, leading to more effective and safter insulin dosing recommendations.
Finally, the upgrades include Meter Max override, which builds on the existing Meter Max feature of the Glucommander and allows for nurses to start insulin treatment without waiting for lab values.
“For the past 15 years, Glytec has been at the forefront of developing computer-guided algorithms that make personalized insulin dosing possible. These latest enhancements are just the most recent example of our ongoing commitment to patient safety and improving nursing workflows. Our 22.214.171.124 release includes many enhancements that we can directly attribute to feedback we’ve received by carefully listening to the doctors, nurses, pharmacists and administrators at hospitals across the country who use our platform,” Glytec CCO John Downey said in the release. “With evidence indicating a strong association between timely and accurate glucose management, improved outcomes and lower costs we are finding that health systems are already showing an increasing interest in Glucommander. With these important new innovations, we expect that adoption will expand even more rapidly.”
– This article originally appeared on Drug Delivery Business.